The price-to-earnings ratio for Adma Biologics Inc (NASDAQ: ADMA) is 128.66x, which is above its average ratio. Moreover, the 36-month beta value for ADMA is 0.61. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ADMA is 225.18M and currently, short sellers hold a 4.22% of that float. On September 16, 2024, ADMA’s average trading volume was 3.77M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ADMA) stock’s latest price update
Adma Biologics Inc (NASDAQ: ADMA)’s stock price has increased by 2.49 compared to its previous closing price of 17.65. However, the company has seen a 11.25% increase in its stock price over the last five trading sessions. zacks.com reported 2024-09-13 that If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our “Recent Price Strength” screen.
ADMA’s Market Performance
Adma Biologics Inc (ADMA) has seen a 11.25% rise in stock performance for the week, with a 2.96% gain in the past month and a 67.81% surge in the past quarter. The volatility ratio for the week is 6.54%, and the volatility levels for the past 30 days are at 4.57% for ADMA. The simple moving average for the past 20 days is 3.88% for ADMA’s stock, with a 110.13% simple moving average for the past 200 days.
Analysts’ Opinion of ADMA
Many brokerage firms have already submitted their reports for ADMA stocks, with Raymond James repeating the rating for ADMA by listing it as a “Strong Buy.” The predicted price for ADMA in the upcoming period, according to Raymond James is $5 based on the research report published on July 19, 2023 of the previous year 2023.
Mizuho, on the other hand, stated in their research note that they expect to see ADMA reach a price target of $5. The rating they have provided for ADMA stocks is “Buy” according to the report published on October 13th, 2022.
Raymond James gave a rating of “Strong Buy” to ADMA, setting the target price at $5 in the report published on November 11th of the previous year.
ADMA Trading at 22.13% from the 50-Day Moving Average
After a stumble in the market that brought ADMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.46% of loss for the given period.
Volatility was left at 4.57%, however, over the last 30 days, the volatility rate increased by 6.54%, as shares surge +2.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +61.37% upper at present.
During the last 5 trading sessions, ADMA rose by +11.25%, which changed the moving average for the period of 200-days by +369.87% in comparison to the 20-day moving average, which settled at $17.44. In addition, Adma Biologics Inc saw 300.22% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADMA starting from Guiheen Lawrence P., who sale 9,000 shares at the price of $18.47 back on Sep 09 ’24. After this action, Guiheen Lawrence P. now owns 153,941 shares of Adma Biologics Inc, valued at $166,189 using the latest closing price.
Guiheen Lawrence P., the Director of Adma Biologics Inc, proposed sale 9,000 shares at $16.26 during a trade that took place back on Sep 09 ’24, which means that Guiheen Lawrence P. is holding shares at $146,340 based on the most recent closing price.
Stock Fundamentals for ADMA
Current profitability levels for the company are sitting at:
- 0.25 for the present operating margin
- 0.46 for the gross margin
The net margin for Adma Biologics Inc stands at 0.11. The total capital return value is set at 0.25. Equity return is now at value 20.77, with 9.67 for asset returns.
Based on Adma Biologics Inc (ADMA), the company’s capital structure generated 0.41 points at debt to capital in total, while cash flow to debt ratio is standing at 0.55. The debt to equity ratio resting at 0.7. The interest coverage ratio of the stock is 4.16.
Currently, EBITDA for the company is 29.96 million with net debt to EBITDA at 0.57. When we switch over and look at the enterprise to sales, we see a ratio of 12.93. The receivables turnover for the company is 10.97for trailing twelve months and the total asset turnover is 0.88. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.87.
Conclusion
To wrap up, the performance of Adma Biologics Inc (ADMA) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
